期刊文献+

增免抑瘤合剂合并化疗对卵巢癌大鼠bcl-2、bax基因表达的影响 被引量:8

Effect on bcl-2bax Gene Expression in Rat with Ovarian Cancer Treated by Cisplatin and "Zengmian Yiliu Mixture"
下载PDF
导出
摘要 目的从卵巢癌大鼠bcl-2、bax凋亡相关基因表达的变化,探讨增免抑瘤合剂辅助治疗卵巢癌的作用机制。方法采用DMBA诱发的原发性卵巢癌大鼠模型,随机分为化疗组(DDP化疗)、合并组(化疗结合增免抑瘤合剂灌胃)、中药组(增免抑瘤合剂灌胃)和模型组(生理盐水灌胃)。共治疗2周,比较各组大鼠bcl-2、bax表达及bcl-2/bax变化。结果治疗各组的bcl-2,bcl-2/bax均较模型组下降,差异显著(P<0.01),其中合并组下降最明显,与中药组及化疗组相比,也具有统计学意义(P<0.01)。合并组的bax表达较其余各组明显提高(P<0.01)。本研究凋亡指数曲线与bax曲线趋于一致性,显示增免抑瘤合剂辅助化疗能促进细胞凋亡。合并组平均凋亡指数最高(33.53%),模型组最低(13.35%),各组间具统计学意义(P<0.01)。结论增免抑瘤合剂合并化疗能下调卵巢癌bcl-2表达,提升bax表达,从而下调bcl-2/bax比值,激活卵巢癌细胞的凋亡途径,这可能是其抗癌增效的作用机制之一。 Objective To study the mechanisms of "Zengmian Yiliu Mixture" on the assistant treatment of ovarian cancer by testing the apoptosis related genes of bcl-2,bax of the ovarian cancer rats. nehtods The rat models with primary ovarian cancer were established by ovarian parenchyma clipping method applying DMBA. The rats were randomly divided into 4 groups: chemotherapy group (chemotherapy with DDP),combined group (DDP combined Mixture),herbal group (Mixture)and control group (saline solution ig). After 2-week treatment,the variations and the relativity of bcl-2,bax and bcl-2/bax were compared. Results Compared with the control group, the bcl-2, bcl-2/bax in treatment groups were declined significantly (P〈 0.01). Among the results,the combined group dropped most significantly even compared with the herbal group and chemotherapy group (P〈 0.01). The expression of bax in the combining group increased significantly compared with other groups (P〈 0.01). The study showed the consistency of the apoptosis index curve and the bax curve, indicating that the cell apoptosis could be increased by the Mixture assistant chemotherapy. The highest average apoptosis index was in the combined group (33.53%), and the lowest was the control group(13.35%). It was significant between two groups (P〈 0.01).Conclusions The chemotherapy combined with the Mixture can decline the expression of bcl-2 in the ovarian cancer and increase that of bax, and the ratio of bcl-2/bax can be decreased,and the ovarian cancer cell apoptosis can be accelerated. This may be one of the mechanisms that it could have a better effect on the cancer.
出处 《上海中医药杂志》 北大核心 2006年第7期63-65,共3页 Shanghai Journal of Traditional Chinese Medicine
基金 上海市教委基金资助项目(01C04)
关键词 卵巢癌 增免抑瘤合剂 BCL-2 BAX 动物实验 Ovarian cancer "Zengmian Yiliu Mixture" bcl-2 bax animal experiment
  • 相关文献

参考文献13

二级参考文献73

  • 1Pors K, Paniwnyk Z, Teesdale Spittle P, et al. Alchemix: a novel alkylating anthraquinone with potent activity against anthracyclineand cisplatin-resistant ovarian cancer. Mol Cancer Ther, 2003, 2(7): 607-610.
  • 2Takano M, Kudo K, GotoT, etal. Analysis by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Hum Cell, 2001, 14(4): 267-271.
  • 3Sakamoto M, Kondo A, Kawasaki K, et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell,2001, 14(4): 305-315.
  • 4Schenk PW, Boersma AW, Brandsma JA, et al. SKY1 is involved in cisplatin -induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res, 2001, 61( 19 ):6982-6986.
  • 5Pan B, Yao KS, Monia BP, et al. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide ( ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol, 2002, 63(9): 1699-1707.
  • 6Sellar GC, Watt KP, Li L, et al. The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer. Int J Oncol, 2002, 21(5):929-933.
  • 7YahataH, Kobayashi H, Kamura T, et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol, 2002, 128(11) :621-626.
  • 8Li J, Feng Q, Kim JM, et al. Human ovarian cancer and cisplatin resistance :Possible role of inhibitor of apoptosis proteins. Endocrinology, 2001, 142(1) :370-380.
  • 9Mansouri A, Zhang Q, Ridgway LD, et al. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res, 2003, 13 (6-10): 399-404.
  • 10Okuno S, Sato H, Kuriyama Matsumura K, et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer, 2003, 88(6): 951-956.

共引文献46

同被引文献149

引证文献8

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部